Summary & Overview
HCPCS Level II C9165: Elranatamab-bcmm Injection, 1 mg
HCPCS Level II code C9165 designates a unit dose of elranatamab-bcmm (1 mg) for injection and identifies billing for administration of a specialty oncology biologic. This code matters nationally as it standardizes claims reporting for a high-cost, parenterally administered cancer therapy and supports consistent reimbursement, utilization tracking, and care coordination across outpatient infusion centers and oncology clinics. Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for elranatamab-bcmm injections, payer coverage considerations, common billing modifiers, and typical service settings. The publication summarizes benchmarks and coding guidance relevant to outpatient infusion billing, highlights policy and coverage themes that affect access and prior authorization, and outlines implications for facility and professional claims. Information on associated taxonomies, ICD-10 diagnoses, and related billing codes is noted as unavailable when not provided. This resource is intended for billing professionals, oncology clinic administrators, and policy analysts seeking a clear national perspective on coding and billing for elranatamab-bcmm injections billed with HCPCS Level II code C9165.
Billing Code Overview
HCPCS Level II code C9165 — Injection, elranatamab-bcmm, 1 mg — represents a billed unit for administration of the oncology biologic elranatamab-bcmm. The service type is medication administration of a specialty oncology injectable. The typical site of service is an outpatient infusion or oncology clinic setting where parenteral specialty drug injections are delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma referred for subcutaneous or intravenous administration of the BCMA-directed bispecific monoclonal antibody C9165 (elranatamab-bcmm), billed per milligram. The clinical workflow begins with hematology-oncology evaluation confirming prior lines of therapy and indication for elranatamab. Baseline assessments include complete blood count, metabolic panel, liver function tests, disease markers (e.g., M-protein, free light chains), and evaluation for cytopenias or infection. Prior to the first dose, patients undergo outpatient education on infusion or injection logistics and potential adverse events such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Premedication orders (antipyretic, antihistamine, corticosteroid as indicated) are entered. On day of service, nursing verifies identity, consents, and vitals; the pharmacy prepares the exact milligram dose and documents lot numbers. Administration is performed in an oncology infusion clinic, specialized outpatient infusion center, or hospital outpatient department with monitoring for immediate reactions; the patient remains for observation per protocol (frequently several hours) and receives follow-up phone calls and scheduled clinic visits for toxicity monitoring and response assessment. Billing uses C9165 with the total number of milligrams administered. Documentation includes indication, exact dose in mg, lot/serial numbers, premedications, start and stop times if applicable, patient tolerance, and any adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|